Dossier
clinicaltrials
trial early
A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms
Key claim: An early-phase clinical study is evaluating the safety, tolerability, and pharmacokinetics of the novel investigational agent INCB160058 in patients with myeloproliferative neoplasms.
Abstract
This study is being conducted to assess the Safety, Tolerability, and Pharmacokinetics of INCB160058 in Participants With Myeloproliferative Neoplasms.
Why this matters
INCB160058 joins a growing pipeline of Incyte-developed investigational agents for MPN (alongside INCB057643, INCA033989, INCA035784, INCA036978), reflecting active expansion beyond JAK inhibition. As a first-in-human safety/PK study, it represents the earliest tier of clinical evidence and will require subsequent efficacy readouts before its therapeutic role can be assessed.